On Monday, Geron Corporation (NASDAQ:GERN)’s shares declined -6.05% to $4.04.
Geron Corporation (GERN) declared that John A. Scarlett, M.D., President and Chief Executive Officer, is planned to present at the Bank of America Merrill Lynch 2015 Healthcare Conference in Las Vegas at 3:40 p.m. Pacific Time on Wednesday, May 13. The presentation will comprise a review of the study design of the planned Phase 2 clinical trial of imetelstat in myelofibrosis patients. Janssen Biotech, Inc. (“Janssen”) will be conducting the study.
As part of the study start-up activities, the study design information was posted on clinicaltrials.gov. The list of participating clinical trial sites, counting multiple sites in the United States and Europe, will be uploaded on ongoing basis. The study is not yet open for enrollment.
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies.
Werner Enterprises, Inc. (NASDAQ:WERN)’s shares dropped -5.85% to $27.85.
Werner Enterprises, Inc. (WERN) professional driver Micheal Sheeds was recognized as a recipient of the 2015 Citizen Driver Award with an April 22 unveiling ceremony that renamed the I-10 and exit 581 Petro Stopping Center in San Antonio, Texas, in his honor.
Presented by TravelCenters of America LLC, operator of the TA® and Petro Stopping Centers® travel center brands, the award recognizes professional drivers who inspire public respect and admiration for the truck driving profession.
Werner Enterprises, Inc., a transportation and logistics company, engages in transporting truckload shipments of general commodities in interstate and intrastate commerce. The company operates in two segments, Truckload Transportation Services and Value Added Services.
At the end of Monday’s trade, Impax Laboratories Inc (NASDAQ:IPXL)‘s shares dipped -5.83% to $46.66.
Impax Laboratories Inc (IPXL) declared that the Company will release its first quarter 2015 financial results on Monday, May 11, 2015, after the close of the U.S. financial markets.
The Company will host a conference call and live webcast with the investment community at 4:30 p.m., Eastern Time on May 11, 2015.
Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division.
Mylan NV (NASDAQ:MYL), ended its Monday’s trading session with -5.71% loss, and closed at $71.72.
Mylan NV (MYL) declared that it will host a conference call and live webcast on Tuesday, May 5, 2015, at 4:30 p.m. ET, to review the company’s financial results for the first quarter ended March 31, 2015 and to provide an update on the projected acquisition of Perrigo. Mylan will release its financial results on May 5 after the market closes.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
